Related Experiment Video
Updated: Jun 24, 2026
10:46
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Cytarabine conjugates with biologically active molecules and their potential anticancer activity
Neoplasma
|March 25, 2009
Summary
This review explores arabinosylcytosine (araC) conjugates to improve cancer therapy. Conjugation enhances drug stability and lipophilicity, potentially overcoming limitations of the original arabinosylcytosine (araC) drug.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Oncology
Background:
- Arabinosylcytosine (araC) is a key drug for hematological malignancies.
- Current limitations of araC include poor lipophilicity, enzymatic instability, and requirement for phosphorylation.
- These limitations restrict its therapeutic efficacy and clinical use.
Purpose of the Study:
- To review various conjugates of arabinosylcytosine (araC).
- To explore strategies for enhancing araC's stability, lipophilicity, and therapeutic potential.
- To discuss novel biological activities arising from araC conjugation.
Main Methods:
- Literature review of existing arabinosylcytosine (araC) conjugates.
- Analysis of conjugation sites (N(4), 2, 2', 3', and 5').
- Evaluation of biological activities and therapeutic differences of conjugated compounds.
Main Results:
- Various araC conjugates have been synthesized and studied.
- Conjugation can improve araC's pharmacokinetic properties and stability.
- Some conjugates exhibit distinct or enhanced biological activities compared to unmodified araC.
Conclusions:
- Conjugation represents a promising strategy to overcome araC's limitations.
- Novel araC conjugates offer potential for improved cancer therapeutics.
- Further research into araC conjugates may lead to more effective treatments for hematological malignancies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:19Phase II Reactions: Miscellaneous Conjugation Reactions
Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:14Phase II Conjugation Reactions: Overview
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...